Inhibitors of influenza viruses replication

US9771361B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Kwame Wiredu Nti-Addae · Tewksbury, US
• Michael Waldo · Grafton, US
• Simon Adam O'Neil · Belmont, US
• John Gregg Van Alsten · Framingham, US
• Dainius Macikenas · Watertown, US
• Praveen Mudunuri · Waltham, US
• Yi-Qun Shi · East Brunswick Township, US
• Mark Ledeboer · Acton, US
• Valdas Jurkauskas · Cambridge, US
• Ales Medek · Winchester, US
• Steven Jones · West Chester, US
• Randal Byrn · Wayland, US
• Mohammed Asmal · Newton, US
• Sarah Robertson · Somerville, US
• Wanjung Tsai · Boston, US

Key dates

• Filing date: May 10, 2016
• Grant date: Sep 26, 2017
• Expiry date: May 10, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula:are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.